We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BioMarin Pharmaceutical has a 52 week low of $52.93 and a 52 week high of $94.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33.

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children. BMRN is a #2 ...

From Washington to Wall Street, it's a crazy time for biotech. But as Ultragenyx Pharmaceutical Inc. celebrates its 15th ...

BioMarin Pharmaceutical Inc. has a 1-year low of $60.63 and a 1-year high of $94.85. The company has a market capitalization of $13.63 billion, a price-to-earnings ratio of 32.47, a PEG ratio of 0 ...

As President Trump prepares to announce pharmaceutical tariffs, he has one country, in particular, in his sights: Ireland.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalyst Pharma (CPRX – Research Report), ...